Method for treating disorders related to complement activation
OwnerM. Edward Medof, Feng Lin +1inventors
InventorsM. Edward Medof, Feng Lin, Qing Li
Life of this patent
Estimating the term…
Abstract
A method for treating or preventing a complement activated T-cell mediated disorder in a subject includes administering a therapeutically effective amount of a pharmaceutical composition to the subject. The pharmaceutical composition includes at least one amidine compound or pharmaceutically acceptable salt.
Claims24
A method for treating disorders associated with intraoccular complement activation or T cell autoreactivity in a subject, the method comprising:
- administering a therapeutically effective amount of a pharmaceutical composition to the subject, the pharmaceutical composition including at least one amidine compound or pharmaceutical salt thereof having anti-complement activity, wherein the at least one amidine compound includes the following general formula
- (I):
- wherein R1 and R2 each represent a hydrogen atom or a straight or branched chain alkyl group of 1 to 6 carbons;
- wherein R3 represents a hydrogen, a straight or branched chain alkyl group of 1 to 6 carbon atoms or a group of the formula R4—B—(CH2)n— where
- n is 1 to 2
- B is —O— or —NH— and
- R4 is a hydrogen atom, R5—CO— or
- and
- R5 is a straight or branched chain alkyl group of 1 to 15 carbon atoms;
- and wherein R1 and R3 taken together via 2 to 4 carbon atoms optionally form a ring containing double bonds and straight or branched alkyl groups of 1 to 4 carbon atoms as substituents or a pharmaceutically acceptable salt thereof.
(canceled)
A method of treating T cell mediated autoimmune disorders in a subject, the method comprising:
- administering a therapeutically effective amount of a pharmaceutical composition to the subject, the pharmaceutical composition including at least one amidine compound or pharmaceutical salt thereof having anti-complement activity, wherein the at least one amidine compound includes formula (I):
- wherein R1 and R2 each represent a hydrogen atom or a straight or branched chain alkyl group of 1 to 6 carbons;
- wherein R3 represents a hydrogen, a straight or branched chain alkyl group of 1 to 6 carbon atoms or a group of the formula R4—B—(CH2)n— where
- n is 1 to 2.
- B is —O— or —NH— and
- R4 is a hydrogen atom, R5—CO— or
- and
- R5 is a straight or branched chain alkyl group of 1 to 15 carbon atoms;
- and wherein R1 and R3 taken together via 2 to 4 carbon atoms optionally form a ring containing double bonds and straight or branched alkyl groups of 1 to 4 carbon atoms as substituents or a pharmaceutically acceptable salt thereof.
(canceled)
A method of treating retinal or choroidal degenerative disease in a subject, the method comprising:
- administering a therapeutically effective amount of a pharmaceutical composition to the subject, the pharmaceutical composition including at least one amidine compound or pharmaceutical salt thereof having anti-complement activity, wherein the at least one amidine compound includes the following general formula (I):
- wherein R1 and R2 each represent a hydrogen atom, or a straight or branched chain alkyl group of 1 to 6 carbons;
- wherein R3 represents a hydrogen, a straight or branched chain alkyl group of 1 to 6 carbon atoms or a group of the formula R4—B—(CH2)n— where
- n is 1 to 2.
- B is —O— or —NH— and
- R4 is a hydrogen atom, R5—CO— or
- and
- R5 is a straight or branched chain alkyl group of 1 to 15 carbon atoms;
- and wherein R1 and R3 taken together via 2 to 4 carbon atoms optionally form a ring containing double bonds and straight or branched alkyl groups of 1 to 4 carbon atoms as substituents or a pharmaceutically acceptable salt thereof.
(canceled)
Dependencies are inferred from the claim text.